[go: up one dir, main page]

MX2009013711A - (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulacion sanguinea. - Google Patents

(oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulacion sanguinea.

Info

Publication number
MX2009013711A
MX2009013711A MX2009013711A MX2009013711A MX2009013711A MX 2009013711 A MX2009013711 A MX 2009013711A MX 2009013711 A MX2009013711 A MX 2009013711A MX 2009013711 A MX2009013711 A MX 2009013711A MX 2009013711 A MX2009013711 A MX 2009013711A
Authority
MX
Mexico
Prior art keywords
oxazolidinon
carboxamides
thiophene
substituted
methyl
Prior art date
Application number
MX2009013711A
Other languages
English (en)
Inventor
Susanne Roehrig
Marcus Bauser
Swen Allerheiligen
Elke Dittrich-Wengenroth
Dirk Heimbach
Degenfeld Georges Von
Stefan Heitmeier
Mark Jean Gnoth
Christoph Gerdes
Ulrich Rester
Uwe Saatmann
Adrian Tersteegen
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39731148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009013711(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MX2009013711A publication Critical patent/MX2009013711A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

La invención se refiere a nuevas oxazolidinonas sustituidas, a procedimientos para su preparación, a su uso para el tratamiento y/o profilaxis de enfermedades así como a su uso para la preparación de medicamentos para el tratamiento y/o profilaxis de enfermedades, de forma particular de enfermedades tromboembólicas. (ver fórmulas I,II).
MX2009013711A 2007-06-20 2008-06-07 (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulacion sanguinea. MX2009013711A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007028319A DE102007028319A1 (de) 2007-06-20 2007-06-20 Substituierte Oxazolidinone und ihre Verwendung
PCT/EP2008/004562 WO2008155032A1 (de) 2007-06-20 2008-06-07 Substituierte (oxazolidinon-5-yl-methyl) -2-thiophen-carboxamide und ihre verwendung im gebiet der blutgerinnung

Publications (1)

Publication Number Publication Date
MX2009013711A true MX2009013711A (es) 2010-02-01

Family

ID=39731148

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013711A MX2009013711A (es) 2007-06-20 2008-06-07 (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulacion sanguinea.

Country Status (42)

Country Link
US (2) US8383822B2 (es)
EP (1) EP2170877B1 (es)
JP (1) JP5537421B2 (es)
KR (1) KR101535312B1 (es)
CN (1) CN101821259B (es)
AR (2) AR066981A1 (es)
AU (1) AU2008266525B8 (es)
BR (1) BRPI0813736A2 (es)
CA (1) CA2692166C (es)
CL (1) CL2008001691A1 (es)
CO (1) CO6251281A2 (es)
CR (1) CR11168A (es)
CU (1) CU23820A3 (es)
CY (1) CY1113580T1 (es)
DE (1) DE102007028319A1 (es)
DK (1) DK2170877T5 (es)
DO (1) DOP2009000285A (es)
EC (1) ECSP099807A (es)
ES (1) ES2397799T3 (es)
GT (1) GT200900319A (es)
HN (1) HN2009003424A (es)
HR (1) HRP20130072T1 (es)
IL (1) IL202351A (es)
JO (1) JO2798B1 (es)
MA (1) MA31535B1 (es)
MX (1) MX2009013711A (es)
MY (1) MY150931A (es)
NZ (1) NZ581540A (es)
PA (1) PA8784301A1 (es)
PE (1) PE20090332A1 (es)
PL (1) PL2170877T3 (es)
PT (1) PT2170877E (es)
RS (1) RS52639B (es)
RU (1) RU2481345C2 (es)
SG (1) SG182220A1 (es)
SI (1) SI2170877T1 (es)
SV (1) SV2009003435A (es)
TN (1) TN2009000503A1 (es)
TW (1) TWI413642B (es)
UA (1) UA98793C2 (es)
UY (1) UY31133A1 (es)
WO (1) WO2008155032A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102010028362A1 (de) 2010-04-29 2011-11-03 Bayer Schering Pharma Aktiengesellschaft Herstellverfahren
CN102464658B (zh) * 2010-11-03 2014-04-16 天津药物研究院 噁唑烷酮衍生物及其制备方法和用途
CN103619883A (zh) 2011-01-19 2014-03-05 拜耳知识产权有限责任公司 凝血因子抑制剂的结合蛋白
CN103626749A (zh) * 2012-08-21 2014-03-12 苏州泽璟生物制药有限公司 取代的噁唑烷酮化合物和包含该化合物的药物组合物及其用途
CN103232446B (zh) * 2013-05-17 2015-09-23 天津药物研究院 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途
CN103242307B (zh) * 2013-05-17 2015-08-12 天津药物研究院有限公司 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途
WO2014183667A1 (zh) * 2013-05-17 2014-11-20 天津药物研究院 一种噁唑烷酮衍生物的乙酸溶剂化物及其制备方法和用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE4319041A1 (de) 1992-10-23 1994-04-28 Bayer Ag Trisubstituierte Biphenyle
ES2325045T3 (es) 1996-10-14 2009-08-24 Bayer Healthcare Ag Nuevos derivados de pirazol heterociclilmetil sustituidos y su uso en el tratamiento de enfermedades cardiovasculares.
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
WO2000024227A1 (en) 1998-10-16 2000-04-27 Medical Solutions, Inc. Temperature control system and method for heating and maintaining medical items at desired temperatures
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
ATE303988T1 (de) 1999-06-14 2005-09-15 Lilly Co Eli Inhibitoren von serin proteasen
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
PL356478A1 (en) * 1999-12-21 2004-06-28 Pharmacia & Upjohn Company Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
TWI257389B (en) 2001-06-12 2006-07-01 Lilly Co Eli Pharmaceutical compound
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
EP1451164A2 (en) * 2001-07-12 2004-09-01 PHARMACIA & UPJOHN COMPANY Amide derivatives having improved solubility
UA78232C2 (uk) 2001-09-21 2007-03-15 Брістол-Майерс Сквібб Компані Лактамвмісні сполуки та їх похідні як інгібітори фактора ха
TW200738672A (en) 2001-12-10 2007-10-16 Bristol Myers Squibb Co Intermediated for the preparation of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
PE20040804A1 (es) 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
US7205318B2 (en) 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
DE10322469A1 (de) 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
US7265140B2 (en) * 2003-09-23 2007-09-04 Pfizer Inc Acyloxymethylcarbamate prodrugs of oxazolidinones
CA2773371A1 (en) 2003-11-12 2005-05-26 Daiichi Sankyo Company, Limited Process for producing thiazole derivative
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
JP2005179272A (ja) 2003-12-19 2005-07-07 Yamanouchi Pharmaceut Co Ltd カルボキサミド誘導体のマロン酸塩結晶
DE102004002044A1 (de) * 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
GB0405272D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
BRPI0512273A (pt) * 2004-06-18 2008-02-19 Millennium Pharm Inc inibidores do fator xa
US20060069260A1 (en) * 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
CA2602025A1 (en) 2005-03-31 2006-10-12 Mochida Pharmaceutical Co., Ltd. Tricyclic spiro compound comprising acyl group bound to nitrogen atom in the ring
US20080221063A1 (en) 2005-07-08 2008-09-11 Astrazeneca Ab Heterocyclic Sulfonamide Derivatives As Inhibitors Of Factor Xa
AR057976A1 (es) * 2005-08-29 2008-01-09 Boehringer Ingelheim Int Biarilos sustituidos y su uso como medicamentos.
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102006025314A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Arylsubstituierte Heterozyklen und ihre Verwendung
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
DE102007028406A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung

Also Published As

Publication number Publication date
EP2170877B1 (de) 2012-11-21
MA31535B1 (fr) 2010-07-01
SV2009003435A (es) 2010-08-23
BRPI0813736A2 (pt) 2014-12-30
CR11168A (es) 2010-06-28
AR067057A1 (es) 2009-09-30
ECSP099807A (es) 2010-01-29
AR066981A1 (es) 2009-09-23
MY150931A (en) 2014-03-14
CU23820A3 (es) 2012-06-21
CN101821259B (zh) 2013-10-30
CA2692166A1 (en) 2008-12-24
AU2008266525A1 (en) 2008-12-24
SG182220A1 (en) 2012-07-30
KR20100021615A (ko) 2010-02-25
TWI413642B (zh) 2013-11-01
AU2008266525B8 (en) 2013-09-19
UY31133A1 (es) 2009-01-30
NZ581540A (en) 2012-01-12
HRP20130072T1 (hr) 2013-02-28
PT2170877E (pt) 2013-01-28
PL2170877T3 (pl) 2013-03-29
CL2008001691A1 (es) 2008-12-26
SI2170877T1 (sl) 2013-03-29
US8383822B2 (en) 2013-02-26
CA2692166C (en) 2015-01-27
AU2008266525B2 (en) 2013-09-05
JP2010530383A (ja) 2010-09-09
JP5537421B2 (ja) 2014-07-02
US20100184740A1 (en) 2010-07-22
ES2397799T3 (es) 2013-03-11
CO6251281A2 (es) 2011-02-21
UA98793C2 (ru) 2012-06-25
RU2010101307A (ru) 2011-07-27
PE20090332A1 (es) 2009-04-09
TN2009000503A1 (en) 2011-03-31
CY1113580T1 (el) 2016-06-22
WO2008155032A1 (de) 2008-12-24
US20140057951A1 (en) 2014-02-27
GT200900319A (es) 2011-11-09
IL202351A (en) 2015-10-29
HK1147991A1 (en) 2011-08-26
IL202351A0 (en) 2010-06-30
JO2798B1 (en) 2014-03-15
RS52639B (sr) 2013-06-28
RU2481345C2 (ru) 2013-05-10
EP2170877A1 (de) 2010-04-07
HN2009003424A (es) 2012-01-05
CU20090216A7 (es) 2011-10-14
US8846934B2 (en) 2014-09-30
TW200911797A (en) 2009-03-16
DK2170877T3 (da) 2013-02-11
CN101821259A (zh) 2010-09-01
KR101535312B1 (ko) 2015-07-09
DOP2009000285A (es) 2010-01-31
DE102007028319A1 (de) 2008-12-24
DK2170877T5 (da) 2013-03-04
PA8784301A1 (es) 2009-02-09

Similar Documents

Publication Publication Date Title
WO2008155069A3 (de) Substituierte oxazolidinone und ihre verwendung
TN2009000503A1 (en) Substituted (oxazolidinon-5-yl-methyl) -2-thiophene-carboxamides and use thereof in the field of blood coagulation
UA102065C2 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
MY156777A (en) Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof
TN2009000132A1 (en) Substituted dihydropyrazolones for treating cardiovascular and haematological diseases
JO3199B1 (ar) مركبات 5- فلورو-1h- بيرازولوبيريدينات مستبدلة واستخدامها
PH12012501699A1 (en) Bisaryl-bonded aryltriazolones and use thereof
ATE453642T1 (de) Substituierte phenylaminopyrimidine
MX2016000258A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso.
MX2011012505A (es) Piperidinas sustituidas.
DE502007006625D1 (de) 3-cyano-5-thiazaheteroaryl-dihydropyridine und ihrnkungen
MX2009013709A (es) (oxazolidinon-5-ilmetil)-2-tiofenocarboxamidas sustituidas y su uso en el campo de la coagulación sanguínea.
MX2011012507A (es) Piperidinas sustituidas.
IL194353A0 (en) Lysobactin amides
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
ATE410443T1 (de) Heterocyclyl-substituierte nonadepsipeptide
ATE455789T1 (de) Substituierte nonadepsipeptide
TW200635920A (en) Pyrazinedicarboxamides and their use
ATE489383T1 (de) Isoindolin-1-on-, isoindolin-3-on- und isoindolin-1,3-dion-derivate und ihre verwendung
TN2015000523A1 (en) Substituted benzoxazoles
DE502006008280D1 (de) Imino-oxazolidine und ihre verwendung als antikoagulantien

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

FG Grant or registration